Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trial

2008 ◽  
Vol 44 (6) ◽  
pp. 840-846 ◽  
Author(s):  
Anne Uyttebroeck ◽  
Stefan Suciu ◽  
Geneviève Laureys ◽  
Alain Robert ◽  
Hélène Pacquement ◽  
...  
Keyword(s):  
T Cell ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma ◽  
Long Term Results

scholarly journals NELARABINE TREATMENT IN ADULT PATIENTS WITH REFRACTORY/ RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA: EXPERIENCE OF A SINGLE CENTRE

2019 ◽  
Vol 64 (4) ◽  
pp. 382-395
Author(s):  
O. A. Gavrilina ◽  
E. S. Kotova ◽  
E. N. Parovichnikova ◽  
V. V. Troitskaya ◽  
A. N. Sokolov ◽  
...  
Keyword(s):  
T Cell ◽  
Acute Lymphoblastic Leukaemia ◽  
Conflict Of Interest ◽  
Lymphoblastic Leukaemia ◽  
Infectious Complications ◽  
Adult Patients ◽  
Long Term Results ◽  
Single Centre ◽  
Poor Efficacy

Introduction. Modern therapy for relapses and resistant forms of T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL/ LBL) shows poor efficacy. The use of nelarabine can improve the results of therapy in patients with refractory/relapsed T-ALL/LBL.Aim. To evaluate the efficacy and toxicity of nelarabine treatment combined with etoposide and cyclophosphamide in adult patients with refractory/relapsed T-ALL/LBL.Materials and methods. During the 2012–2018 period, 10 patients with refractory/relapsed T-ALL aged from 19 to 41 underwent nelarabine treatment. The patients received from 1 to 3 chemotherapy courses including nelarabine 650 mg/m2 (days 1 to 5), etoposide 100 mg/m2 and cyclophosphamide 440 mg/m2 (days 8 to 12). All the patients having achieved complete remission (СR) underwent transplantation of allogeneic haematopoietic stem cells (allo-HSCT). The development of toxic sequelae (myelosuppression, neurotoxicity, incidence of infectious complications) was considered after each chemotherapy course.Results. Out of 10 patients who received 1–2 chemotherapy courses, 6 (60 %) achieved CR. These 6 patients subsequently underwent allo-HSCT, which was followed by early relapse in 3 (50 %) of 6 patients and the death of 1 patient in persisting CR caused by infectious complications. Only 2 of 6 patients have been monitored for 1.5 years after the allo-HSCT. The five-year overall survival rate in relapsed patients came to 18 %. In terms of toxic sequelae, myelosuppression and infectious complications were observed in all patients. Neurotoxicity was noted in 3 (30 %) out of 10 patients, with two of them experiencing it after each course and one patient — only following the third course of nelarabine treatment.Conclusion. The use of nelarabine for the treatment of refractory/relapsed T-ALL/LBL provides the opportunity to achieve CR in 60 % of cases, as well as to perform allo-HSCT. However, long-term results are not very optimistic, thus further research is required.Conflict of interest: the authors declare no conflict of interest.Financial disclosure: the study had no sponsorship.

Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

2007 ◽  
Vol 48 (9) ◽  
pp. 1745-1754 ◽  
Author(s):  
Anne Uyttebroeck ◽  
Vera Vanhentenrijk ◽  
Anne Hagemeijer ◽  
Nancy Boeckx ◽  
Marleen Renard ◽  
...  
Keyword(s):  
T Cell ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Lymphoblastic Lymphoma

Long-term results of the HEAVD protocol for adult acute lymphoblastic leukaemia

1991 ◽  
Vol 27 (4) ◽  
pp. 441-447 ◽  
Author(s):  
Renato Bassan ◽  
Raffaele Battista ◽  
Anna D'Emilio ◽  
Piera Viero ◽  
Patrizia Dragone ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Long Term Results
Sign in / Sign up

Export Citation Format

Share Document